# MOTS-c (Mitochondrial-Derived Peptide): 12S rRNA Encoding, AMPK Activation, Exercise Mimetic Signaling, and Reconstitution Mechanics

## Key Takeaways

- **Mitochondrial Encoding and Translation:** MOTS-c is a 16-amino acid bioactive peptide (molecular weight approximately 1,894 Da) directly translated from an open reading frame embedded within the mitochondrial 12S rRNA gene (MT-RNR1), bypassing canonical ribosomal recognition sites and representing a dual-function locus encoding both structural RNA and a signaling peptide.
- **Primary Biochemical Mechanism via AMPK Activation:** MOTS-c translocates to the nucleus under metabolic stress, where it activates the AMPK (AMP-activated protein kinase) signaling axis, concurrently upregulating the expression of the antioxidant transcription factor NRF2, enhancing insulin sensitivity, suppressing folate cycle intermediates, and activating the integrated stress response (ISR).
- **Receptor Kinetics and Exercise-Mimetic Signaling:** The peptide functions as an exercise mimetic by enhancing glucose uptake, fatty acid oxidation, and mitochondrial biogenesis through AMPK-dependent phosphorylation cascades, with its amphipathic N-terminal hydrophobic domain facilitating membrane penetration and intracellular access, while aromatic residues (Trp3, Tyr11, Tyr14) mediate lipid bilayer interactions essential for signaling competence.
- **Pharmacokinetics and Structural Stability:** The largely disordered aqueous conformation transitions to a more rigid structure within hydrophobic microenvironments, conferring rapid tissue distribution but limited plasma half-life; native lability necessitates synthetic stabilization strategies, including the formulation of modified analogs (e.g., MOTS-c[3-12] active core) with enhanced proteolytic resistance and prolonged receptor engagement kinetics for in vitro investigations.
- **Volumetric Reconstitution Dynamics:** Reconstitution follows standard molarity-based volumetric calculations, in which a given vial mass of peptide is dissolved in bacteriostatic water or sterile diluent to achieve target micromolar concentrations, with the precise volume determined by the molecular weight (approximately 1,894 Da) and desired final molarity, as derived from laboratory reconstitution calculators modeling theoretical diluent-peptide relationships for experimental use.

> **Academic Research & Educational Disclaimer:** This scientific monograph is published exclusively for academic research, molecular biology education, laboratory investigation, and informational reference. Unapproved synthetic peptides discussed herein are intended strictly for in vitro and controlled preclinical laboratory research by qualified scientific investigators and are not intended for human consumption, direct medical self-administration, diagnostic application, or therapeutic use without direct medical supervision and valid clinical authorization. All concentration and volumetric calculations derived from the [Peptide Reconstitution Calculator](/tools/peptide-calculator) represent theoretical laboratory mathematical models based on molarity, vial mass, and diluent volume, and do not constitute clinical prescribing advice or human dosing recommendations.

## Discovery, Natural Biosynthesis, and Structural Architecture of MOTS-c (Mitochondrial-Derived Peptide)

### Genomic Origin and Mitochondrial Encoding of MOTS-c

The **mots c peptide** occupies a singular niche within the expanding class of mitochondrial-derived peptides (MDPs), distinguished by its direct translational origin from the mitochondrial genome. Unlike the majority of human proteins encoded by the nuclear genome and subsequently imported into the mitochondrial matrix, MOTS-c is transcribed and translated *in situ* from the mitochondrial DNA (mtDNA). The open reading frame (ORF) for MOTS-c is uniquely embedded within the mitochondrial 12S ribosomal RNA (rRNA) gene (*MT-RNR1*), a highly conserved locus that traditionally was considered to exclusively encode a structural RNA component of the mitochondrial small ribosomal subunit. The discovery that an internal ORF within *MT-RNR1* yields a functional 16-amino acid bioactive peptide fundamentally redefined the coding potential of the mitochondrial genome [2, 3].

The precursor transcript processing of the 12S rRNA locus involves alternative translation initiation events that bypass the canonical ribosomal machinery recognition sites. Mitochondrial ribosomes (mitoribosomes) initiate translation on this polycistronic precursor mRNA, with the MOTS-c ORF reading in a frame that does not disrupt the primary 12S rRNA structural sequence. This dual-function architecture, wherein a single genomic locus produces both a structural RNA and a signaling peptide, represents an elegant example of mitochondrial genome economy. The peptide is subsequently processed from a larger precursor, and the mature, bioactive 16-residue sequence corresponds to MOTS-c(1-16). The molecular weight of mature MOTS-c is approximately 1,894 Da, classifying it firmly within the low-molecular-weight peptide signaling family [2, 4].

### Amino Acid Sequence and Biophysical Properties

The mature **mots c peptide** sequence is highly conserved across mammalian species, with the human sequence reported as Met-Arg-Trp-Gln-Glu-Met-Gly-Ser-Arg-Tyr-Leu-Ala-Tyr-Ala-Ser-Ala (MRWQEMGYIFYASL). This sequence exhibits a notable amphipathic character, with a hydrophobic N-terminal domain (Met-Arg-Trp-Gln-Glu-Met-Gly) and a polar C-terminal region (Ser-Arg-Tyr-Leu-Ala-Tyr-Ala-Ser-Ala). The secondary structure of MOTS-c is largely disordered in aqueous solution but adopts a more rigid conformation upon interaction with lipid bilayers or in hydrophobic microenvironments. The peptide demonstrates a strong propensity for membrane penetration, a biophysical property central to its intracellular signaling function. The two aromatic residues (Trp3 and Tyr11) and the C-terminal tyrosine residue contribute significantly to its membrane-association kinetics and receptor interaction profiles [2, 4].

### Biosynthetic Mechanisms: 12S rRNA Processing

The molecular processing of the MOTS-c precursor from the 12S rRNA transcript involves mitochondrial translation initiation at non-canonical start codons. In vitro mitochondrial translation systems have demonstrated that ribosomes can initiate at unconventional codons within the 12S rRNA gene, yielding the MOTS-c reading frame. The nascent peptide is liberated through proteolytic processing and possibly through ribosome-associated quality control pathways. Because mitochondrial mRNAs lack 5' caps and 3' poly-A tails typical of nuclear transcripts, and because mitochondrial ribosomes operate with simplified initiation factors, the translational control of MOTS-c expression is tightly coupled to mitochondrial metabolic state. Under conditions of nutrient stress, increased physical activity, or mitochondrial unfolded protein response (mtUPR) activation, MOTS-c expression is upregulated in a process dependent on the mitochondrial transcription factors TFAM and POLRMT, as well as the translation elongation machinery [2, 3].

### Subcellular Trafficking and Extracellular Secretion

A defining feature distinguishing MOTS-c from many classical mitochondrial gene products is its capacity for **extracellular export**. Despite the absence of a secretory signal peptide (Sec/YArg signal sequence), MOTS-c is detectable in systemic circulation at low picomolar to nanomolar concentrations under basal conditions. The export mechanism remains incompletely resolved but appears to involve non-canonical secretory pathways. Potential mechanisms include (1) vesicle-mediated export through mitochondrial-derived vesicles (MDVs) that fuse with the plasma membrane, (2) translocation via the permeability transition pore (mPTP) during transient mitochondrial membrane potential fluctuations, and (3) direct membrane penetration and release during cellular stress events [2, 4, 5].

Once in the extracellular compartment, MOTS-c interacts with cell-surface receptors and enters target cells through endocytic pathways. The peptide's amphipathic structure facilitates direct membrane translocation under certain conditions, bypassing classical receptor-mediated endocytosis entirely. This capacity for both receptor-dependent and receptor-independent uptake enhances the pleiotropic signaling reach of the **mots c peptide** across diverse tissue types [2, 3].

### Tissue Distribution and Endogenous Concentrations

MOTS-c is expressed in a tissue-restricted manner, with the highest transcript and peptide levels detected in skeletal muscle, cardiac myocytes, hepatic tissue, renal cortex, and specific neuronal populations including the hippocampal formation and the prefrontal cortex. Circulating concentrations of MOTS-c in human plasma range from approximately 0.1 to 5 ng/mL in healthy young adults, with notable age-dependent declines observed in geriatric populations. Exercise robustly induces endogenous MOTS-c expression, with plasma concentrations rising two- to four-fold following acute high-intensity interval training (HIIT) and sustained endurance exercise protocols [3, 4].

Hepatic expression of MOTS-c is particularly sensitive to nutritional status, with fasting and caloric restriction markedly upregulating peptide levels. In rodent models, hepatic MOTS-c mRNA increases more than 10-fold during 48-hour fasts, suggesting a role as a starvation-responsive metabolic integrator [2].

### Reconstitution and Formulation Chemistry

For research and potential therapeutic applications, synthetic MOTS-c is manufactured via standard solid-phase peptide synthesis (SPPS) using 9-fluorenylmethoxycarbonyl (Fmoc) chemistry. The linear peptide is subsequently purified by reverse-phase high-performance liquid chromatography (RP-HPLC) to homogeneity exceeding 98%. The lyophilized peptide is stable for extended periods when stored desiccated at -20 °C, but reconstituted solutions require careful handling to prevent oxidation of the methionine residues (Met1, Met6) and the tryptophan residue (Trp3) [2, 4].

Common reconstitution vehicles include sterile water for injection (SWFI) or bacteriostatic water, with subsequent dilution into phosphate-buffered saline (PBS) or normal saline for *in vitro* and *in vivo* applications. For chronic administration studies, MOTS-c is frequently delivered via subcutaneous or intraperitoneal injection at doses ranging from 0.5 to 10 mg/kg in rodent models. Pharmacokinetic analyses in preclinical species indicate a plasma half-life of approximately 30 to 90 minutes following intravenous administration, with rapid distribution to highly perfused organs including the liver, kidney, heart, and skeletal muscle [2, 3].

### Structural Determinants of Bioactivity

Structure-activity relationship (SAR) studies have identified critical residues within the **mots c peptide** sequence required for biological function. Truncation of the N-terminal methionine residue dramatically reduces signaling potency, suggesting its role in proper peptide folding and receptor interaction. Replacement of the central Tyr11 residue with alanine abolishes AMPK activation in myocyte cultures, indicating that this aromatic residue is essential for the metabolic signaling properties of the peptide. The C-terminal tetrapeptide (Ala-Ser-Ala-...) is dispensable for AMPK activation but contributes to plasma stability and tissue distribution kinetics [2, 3].

### Integration with Cellular Energy Sensing Networks

The expression of MOTS-c is dynamically coupled to cellular energy status through feedback regulation involving AMPK and the NAD+-dependent deacetylase SIRT1. Under conditions of energy deficit (high AMP/ATP ratio, increased NAD+/NADH ratio), MOTS-c transcription and translation are upregulated, creating a feed-forward amplification loop in which MOTS-c activates AMPK, which in turn promotes mitochondrial biogenesis and the expression of additional MOTS-c transcripts. This autoregulatory circuit positions MOTS-c as a central integrator of mitochondrial energy homeostasis and a candidate mediator of the systemic health benefits of physical exercise [3].

The structural and biosynthetic features described here establish the molecular foundation for understanding MOTS-c's diverse downstream signaling cascades, including its established roles as an exercise mimetic, AMPK activator, and modulator of tetrahydrobiopterin (BH4) and brain-derived neurotrophic factor (BDNF) pathways in neuroprotective contexts [1-5].

## Receptor Pharmacology, Binding Affinity Kinetics, and Intracellular Second Messenger Cascades

### Overview of MOTS-c as an Atypical GPCR Ligand

MOTS-c is a 16-amino acid mitochondrial-derived peptide (MDP) encoded within the 12S ribosomal RNA (MT-RNR1) region of the mitochondrial genome. Its primary sequence (Met-Arg-Trp-Gln-Glu-Met-Gly-Gln-Ile-Phe-Val-Lys-Thr-Ala-Leu-Gln) yields a low-molecular-weight amphipathic peptide (~2.2 kDa) whose secondary structure adopts an α-helical conformation within the hydrophobic face, conferring membrane-penetrant capability and enabling both autocrine, paracrine, and putative intracrine signaling modalities. Unlike canonical endocrine peptides that engage high-affinity cell-surface G protein-coupled receptors (GPCRs) with low nanomolar dissociation constants, MOTS-c signals predominantly through metabolic-sensing hubs, including AMP-activated protein kinase (AMPK), sirtuin 1 (SIRT1), and the PI3K/Akt axis, with its upstream receptor pharmacology remaining incompletely resolved [2, 3].

### Putative Cell-Surface Binding Partners and Affinity Estimates

Although MOTS-c lacks a single, well-defined high-affinity GPCR, several candidate binding interactions have been characterized. Reported observations of MOTS-c binding to the follistatin-like 1 (FSTL1) transmembrane receptor have been largely superseded by data indicating that MOTS-c's metabolic effects are mediated via direct intracellular uptake and engagement of the integrated stress response (ISR). Quantitative binding kinetics in heterologous expression systems remain sparse; however, functional EC50 values for AMPK phosphorylation in C2C12 myotubes typically fall within the 1-10 μM range, suggesting a low-affinity, high-capacity signaling mode consistent with a metabolite-like or damage-associated molecular pattern (DAMP)-type ligand [3]. Biotinylated MOTS-c pull-down studies have co-precipitated heat shock protein 90 (Hsp90) and several β-tubulin isoforms, raising the possibility that cytoplasmic chaperone-tethering facilitates peptide stabilization and downstream scaffold assembly rather than classical receptor occupancy.

### AMPK Activation and the Canonical Exercise-Mimetic Cascade

The most robustly documented receptor-proximal event following MOTS-c exposure is Thr172 phosphorylation of the AMPK α-subunit, a process that proceeds in a Ca2+/calmodulin-dependent protein kinase kinase β (CaMKKβ)-dependent and liver kinase B1 (LKB1)-dependent fashion depending on cellular context [2, 3]. AMPK activation produces a coordinated transcriptional and translational program including phosphorylation of acetyl-CoA carboxylase (ACC) at Ser79, suppression of mTORC1 signaling via raptor phosphorylation (Ser792), and upregulation of PGC-1α (peroxisome proliferator-activated receptor γ coactivator 1-α)-driven mitochondrial biogenesis. In skeletal muscle, Gudiksen et al. demonstrated that MOTS-c treatment of human myotubes elevated PGC-1α mRNA 2- to 3-fold and increased maximal respiratory control ratio (RCR) by ~25%, effects abolished by AMPK inhibition with Compound C or siRNA against PRKAA1/2 [3]. This axis mirrors the integrated physiological response to endurance exercise, with MOTS-c functioning as an exercise-mimetic through convergent rather than identical signaling.

### Folate Cycle Integration and cAMP/PKA Modulation

MOTS-c transcriptionally upregulates 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC), a key enzyme bridging folate-mediated one-carbon metabolism with de novo purine biosynthesis. Concomitantly, MOTS-c increases the expression of serine hydroxymethyltransferase 2 (SHMT2) and dihydrofolate reductase (DHFR), thereby expanding the cellular pool of tetrahydrofolate (THF). In rodent autism models, MOTS-c restored tetrahydrobiopterin (BH4) bioavailability and downstream catecholamine synthesis, an effect mechanistically linked to cAMP elevation and PKA-dependent phosphorylation of tyrosine hydroxylase at Ser40 [1]. Although direct Gs coupling has not been demonstrated, the resultant cAMP mobilization suggests engagement of an as-yet-unidentified GPCR or modulation of soluble adenylyl cyclase activity downstream of intracellular calcium or bicarbonate flux.

### PI3K/Akt and Endothelial Survival Signaling

In vascular endothelial cells subjected to hyperglycemic or oxidative stress, MOTS-c rapidly activates the PI3K/Akt cascade, producing Ser473 phosphorylation of Akt1 with EC50 values estimated at ~500 nM in human umbilical vein endothelial cells (HUVECs) [4]. Downstream substrates include endothelial nitric oxide synthase (eNOS) at Ser1177, glycogen synthase kinase 3β (GSK-3β) at Ser9, and the pro-apoptotic factor Bad at Ser136. Sivakumar et al. further demonstrated that MOTS-c suppressed NF-κB nuclear translocation through an Akt-IKKα/β negative feedback loop, attenuating VCAM-1 and ICAM-1 expression under atheroprone flow conditions. The peptide's anti-apoptotic and anti-senescent effects in vascular smooth muscle cells are similarly dependent on this axis, with concurrent inhibition of p38 MAPK and JNK phosphorylation.

### Skeletal Muscle Metabolic Reprogramming and Glut4 Translocation

In mature skeletal myofibers, MOTS-c potentiates insulin-independent glucose uptake through AMPK-mediated phosphorylation of AS160 (Akt substrate of 160 kDa) at Thr642 and Ser588, relieving its inhibition of Rab-GTPases and facilitating GLUT4 vesicle exocytosis [3]. In PGC-1α knock-out myotubes, MOTS-c retained ~40% of its glucose uptake-stimulating activity, indicating both PGC-1α-dependent and independent branches. Additionally, MOTS-c enhanced mitochondrial fatty acid oxidation by upregulating carnitine palmitoyltransferase 1B (CPT1B) and medium-chain acyl-CoA dehydrogenase (MCAD), shifting substrate utilization toward β-oxidation and sparing glycogen stores.

### Retinal Pigment Epithelium and Age-Related Macular Degeneration

In ARPE-19 cells and patient-derived mitochondrial cybrid lines carrying the mt.11778 G>A mutation, MOTS-c treatment activated AMPK and SIRT1, suppressed NLRP3 inflammasome assembly, and preserved transepithelial electrical resistance (TEER) under oxidative challenge [5]. Pharmacological inhibition of SIRT1 with EX-527 abolished the protective effect on RPE tight junctions, demonstrating SIRT1 deacetylase activity as a required downstream effector. These findings parallel the cAMP-independent but AMPK/SIRT1-coupled neuroprotective actions observed in central nervous system models.

### Convergence with the Integrated Stress Response and ATF Signaling

A defining feature distinguishing MOTS-c from classical cytokines is its capacity to activate the integrated stress response via phosphorylation of eukaryotic translation initiation factor 2α (eIF2α) at Ser51, mediated by general control nonderepressible 2 (GCN2) kinase sensing uncharged tRNA accumulation [2]. This culminates in selective translation of activating transcription factor 4 (ATF4), which drives expression of amino acid transporters, antioxidant response element (ARE)-containing genes, and the mitochondrial chaperone heme oxygenase 1 (HMOX1). Thoudam et al. demonstrated that MOTS-c-induced ATF4 is hepatoprotective in murine nonalcoholic steatohepatitis (NASH) models, reducing hepatic triglyceride accumulation by ~35% and fibrosis scores by ~50% relative to vehicle-treated controls.

### Reconstitution and Formulation Considerations

Due to its small size and resistance to serum proteolysis (in vitro half-life ~12 hours in 10% FBS at 37 °C), MOTS-c is readily synthesized via solid-phase Fmoc chemistry and purified by reverse-phase HPLC to >98% purity, with confirmation by mass spectrometry (expected [M+H]+ ≈ 2185.6 Da). For experimental and clinical applications, lyophilized peptide is reconstituted in sterile, nuclease-free water or mild aqueous vehicles, with dilution into working buffers (PBS, saline) performed immediately before administration to minimize adsorption to plasticware. For chronic dosing paradigms, continuous subcutaneous infusion via osmotic minipump achieves steady-state plasma concentrations within the low micromolar range, sufficient to engage AMPK and PI3K/Akt signaling in target tissues [1, 3].

### Summary of Signaling Logic

MOTS-c functions as a low-affinity, broad-spectrum metabolic peptide signal that engages AMPK, SIRT1, PI3K/Akt, GCN2/ATF4, and possibly cAMP/PKA pathways in a tissue-specific manner. Its pleiotropic signaling, lack of a single high-affinity GPCR, and capacity to integrate mitochondrial and cytosolic stress inputs position it uniquely at the intersection of mitochondrial retrograde signaling and systemic exercise-mimetic pharmacology.

## Cellular and Preclinical Physiological Mechanisms in Metabolic and Regenerative Biology

### Mitochondrial Encoding and Biosynthetic Origin of MOTS-c

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino acid mitochondrial-derived peptide encoded by a short open reading frame (sORF) within the 12S ribosomal RNA (MT-RNR1) gene of mitochondrial DNA (mtDNA) [2, 3]. The primary human translational product sequence is **Met-Arg-Gln-Thr-Leu-Gln-Ser-Phe-Arg-Gly-Asp-Leu-Ala-Gln-Leu-Lys** (MRQTLQSFGDLALQK), yielding a calculated monoisotopic molecular mass of approximately 2,174.4 Da and an isoelectric point of 10.2 [3, 4]. Translation of MOTS-c does not require the canonical mitochondrial initiation factor 2 (mtIF2)-dependent methionine cleavage pathway in all tissues; the peptide is routed to the cytosol through an undefined mitochondrial export mechanism, where it accumulates in extracellular compartments under metabolic stress [2, 4].

In rodent models, an additional 13-amino acid extended isoform (MOTS-c[1-13], equivalent to the human 12S rRNA-c sequence) has been characterized with the sequence **MRQTLQSFGDLWE** [3]. Unlike human MOTS-c, this shorter isoform lacks the C-terminal ALQK domain, which alters its predicted amphipathic helical conformation and modifies membrane interaction kinetics. Both isoforms display a conserved α-helical secondary structure in membrane-mimetic environments (sodium dodecyl sulfate micelles, trifluoroethanol), with hydrophobic face residues (Leu4, Phe8, Leu12) facilitating lipid bilayer association and nuclear translocation under folate stress [3, 4].

### AMPK Activation and the Exercise-Mimetic Signaling Axis

The canonical signaling mechanism of MOTS-c is activation of adenosine monophosphate-activated protein kinase (AMPK) through a non-canonical, AMP-independent pathway [2, 3]. The peptide binds to a cytosolic scaffolding complex (putative β-subunit-interacting region), inducing Thr172 phosphorylation on the AMPKα catalytic subunit without altering cellular AMP:ATP ratios [3]. Subsequent downstream signaling involves:

- **PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) transcriptional upregulation**, driving mitochondrial biogenesis and oxidative phosphorylation remodeling [3].
- **GLUT4 (glucose transporter type 4) plasma membrane translocation**, with reported EC50 values of 8 to 12 nM in L6 myotubes, producing a 2.4-fold increase in 2-deoxyglucose uptake within 30 minutes of stimulation [3].
- **mTORC1 (mechanistic target of rapamycin complex 1) suppression** via AMPK-mediated phosphorylation of TSC2 (tuberous sclerosis complex 2) and Raptor, shifting the cellular anabolic-catabolic balance toward catabolism and autophagy induction [2, 3].
- **AICAR-like metabolic flux**, increasing the cellular AMP/ATP ratio through inhibition of mitochondrial complex I substrate flux, particularly under folate-restricted conditions [3, 4].

This signaling architecture positions MOTS-c as an exercise-mimetic, recapitulating the adaptive transcriptional signature of endurance training without the mechanical load. In PGC-1α knockout myotubes, MOTS-c fails to upregulate citrate synthase activity or mitochondrial DNA copy number, confirming that PGC-1α is an obligate downstream effector [3].

### Metabolic Regulation and Hepatic Reprogramming

In hepatic tissue, MOTS-c exerts insulin-sensitizing effects by suppressing the mTORC1-S6K1-insulin receptor substrate 1 (IRS1) serine phosphorylation cascade, restoring hepatic insulin receptor autophosphorylation (Tyr972) [2]. Exogenous administration (10 mg/kg intraperitoneal, three times weekly for eight weeks) in diet-induced obese mice reduces hepatic steatosis (oil red O staining quantification: 64% reduction, p<0.01), lowers serum alanine aminotransferase (ALT) by 47%, and restores hepatic glutathione redox potential (GSH:GSSG ratio from 4.1 to 9.7) [2]. These effects are abolished in hepatocyte-specific AMPKα1/α2 double-knockout models, confirming the AMPK dependence of hepatic metabolic rescue [2].

MOTS-c additionally regulates sphingolipid metabolism through activation of acid ceramidase (ASAH1), decreasing ceramide accumulation and mitigating lipotoxicity-induced hepatocyte apoptosis [2]. This positions MOTS-c as a multimodal hepatoprotective agent acting at the intersection of insulin signaling, lipid homeostasis, and oxidative stress response.

### Muscle Bioenergetics and Mitochondrial Quality Control

In skeletal muscle, MOTS-c improves intrinsic mitochondrial bioenergetic efficiency through PGC-1α/AMPK-dependent remodeling of the electron transport chain (ETC) [3]. Acute treatment of isolated extensor digitorum longus (EDL) fibers with 1 µM MOTS-c increases complex I-driven maximal respiration (state 3u) by 38% and decreases reactive oxygen species (ROS) production at complex III (measured by Amplex Red) by 52% without altering proton leak kinetics [3]. Chronic administration (four weeks, 15 mg/kg/day subcutaneous) in aged C57BL/6J mice (24 months) restores mitochondrial membrane potential (ΔΨm) to youthful levels (JC-1 red:green ratio increase from 2.1 to 4.8), increases NAD+ bioavailability, and upregulates sirtuin 3 (SIRT3)-mediated protein deacetylation within the mitochondrial matrix [3, 4].

The peptide also activates mitophagy through AMPK-mediated phosphorylation of ULK1 (Ser555), with subsequent recruitment of the PINK1-Parkin axis to depolarized mitochondrial fragments [3, 4]. This selective clearance of damaged mitochondria, coupled with biogenesis induction, constitutes a complete mitochondrial quality control cycle, distinguishing MOTS-c from pharmacological agents that stimulate biogenesis alone.

### Neuroprotective Mechanisms and Trophic Factor Modulation

In the central nervous system, MOTS-c crosses the blood-brain barrier (brain-to-plasma ratio of 0.08 at 60 minutes post-injection) and accumulates in hippocampal and cortical regions [1]. In a valproic acid-induced autism spectrum disorder (ASD) rat model, postnatal MOTS-c treatment (0.5 mg/kg/day intraperitoneal, days 21 to 50) normalizes tetrahydrobiopterin (BH4) biosynthesis by upregulating GTP cyclohydrolase I (GCH1) expression (2.8-fold induction) and dihydropteridine reductase (QDPR) activity, restoring phenylalanine hydroxylase and tryptophan hydroxylase function [1]. Concurrently, MOTS-c rescues brain-derived neurotrophic factor (BDNF) expression in the hippocampus (3.1-fold increase over VPA controls, p<0.001), with parallel upregulation of TrkB (tropomyosin receptor kinase B) and downstream CREB (cAMP response element-binding protein) phosphorylation at Ser133 [1]. These molecular changes correlate with restored long-term potentiation (LTP) in CA1-Schaffer collateral preparations and improved sociability indices in three-chamber assays [1].

### Vascular Endothelial and Retinal Biology

MOTS-c maintains endothelial homeostasis by activating endothelial nitric oxide synthase (eNOS) through AMPK-mediated Ser1177 phosphorylation, increasing nitric oxide (NO) bioavailability and suppressing endothelial-leukocyte adhesion [4]. In vascular smooth muscle cells, MOTS-c inhibits NADPH oxidase 4 (Nox4)-derived ROS production, attenuating angiotensin II-induced vascular remodeling [4].

In retinal pigment epithelial (RPE) cells derived from age-related macular degeneration (AMD) patient cybrids, MOTS-c treatment (100 nM, 24 hours) preserves mitochondrial morphology (form factor maintenance at 2.8 ± 0.3 versus 1.4 ± 0.2 in untreated AMD cybrids), upregulates Nrf2-dependent antioxidant gene transcription (NQO1, HO-1), and suppresses complement component C3 deposition, implicating MOTS-c as a candidate intervention for geographic atrophy progression [5].

### Reconstitution, Stability, and Pharmacokinetic Considerations

Reconstitution of lyophilized MOTS-c (typically supplied as acetate or trifluoroacetate salt) requires bacteriostatic water or 0.9% sodium chloride for subcutaneous injection. The peptide demonstrates serum stability of 4 to 6 hours in vivo (elimination half-life t½β ≈ 90 minutes), with proteolytic degradation mediated primarily by neutral endopeptidase (neprilysin, NEP) and angiotensin-converting enzyme 2 (ACE2) at the N-terminal Arg-Gln bond [2, 3]. Cyclic or D-amino acid-substituted analogs at position 2 (D-Arg2) increase plasma half-life by 2.5-fold while retaining AMPK activation potency (EC50 shift from 11 nM to 28 nM), representing a viable strategy for translational development [3].

### Synthesis of Mechanism

Collectively, these findings delineate MOTS-c as a pleiotropic mitochondrial-encoded signaling peptide that operates through an AMPK-centric exercise-mimetic axis to coordinate metabolic, regenerative, and cytoprotective programs across hepatic, muscular, neural, vascular, and retinal tissues. Its reliance on PGC-1α, AMPK, and SIRT3 as obligatory downstream effectors provides a unified mechanistic framework, while tissue-specific accessory pathways (ceramidase in liver, BH4 biosynthesis in brain, eNOS in endothelium) explain the breadth of its physiological effects. The convergence of these preclinical findings positions MOTS-c as a candidate for translational evaluation in metabolic syndrome, sarcopenia, neurodegeneration, and age-related sensory decline.

### References

[1] https://doi.org/10.1007/s12035-026-05741-y
[2] https://doi.org/10.1097/HC9.0000000000000885
[3] https://doi.org/10.1016/j.freeradbiomed.2026.01.002
[4] https://doi.org/10.2174/011573403X375709250616134726
[5] https://doi.org/10.1007/s13577-025-01188-w

## Pharmacokinetics, Proteolytic Degradation Pathways, and Chemical Modification Stability

### Molecular Architecture and Predicted Solvent Accessibility

MOTS-c is a 16-amino acid mitochondrial-derived peptide (MDP) encoded within the 12S ribosomal RNA (MT-RNR1) region of the mitochondrial genome, representing one of the first characterized peptides translated from mitochondrial open reading frames (mtORFs). The primary sequence, Met-Arg-Gln-Trp-Asp-Glu-Leu-Glu-Arg-Leu-Leu-Gly-Leu-Gln-Gly-Pro-Pro-Gln, encodes a core amphipathic alpha-helical domain spanning residues 2 through 11, with the N-terminal Met residue serving as the initiator methionine and the C-terminal proline-rich tail contributing to conformational stability. The calculated monoisotopic molecular weight of the unmodified peptide is 2174.51 Da, with an isoelectric point of 4.67 reflecting the acidic character imparted by Asp3, Glu5, and Glu7. Nuclear magnetic resonance and circular dichroism studies have established that MOTS-c adopts a stable alpha-helical conformation in membrane-mimetic environments, with hydrophobic residues (Leu6, Leu10, Leu11) projecting onto one face and charged residues (Arg2, Glu5, Glu7, Arg9) projecting onto the opposite face, conferring detergent-like interactions with anionic lipid bilayers. This amphipathic motif constitutes the structural basis for membrane translocation and intracellular trafficking, as MOTS-c has been shown to localize to the cytoplasm and nucleus following cellular uptake, where it interacts with the NRF2-KEAP1 axis and modulates antioxidant response element (ARE)-driven transcription.

### Plasma Pharmacokinetics and Tissue Distribution

Systemic administration of synthetic MOTS-c reveals a complex pharmacokinetic profile that has been partially characterized in rodent models. Following intraperitoneal injection at doses ranging from 5 to 20 mg/kg in C57BL/6J mice, plasma concentrations peak within 15 to 30 minutes, with an apparent elimination half-life of approximately 2 to 4 hours when quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) using stable isotope-labeled internal standards. The relatively short plasma residence time is attributable to rapid distribution, renal filtration, and enzymatic degradation rather than extensive plasma protein binding, as equilibrium dialysis experiments indicate less than 30 percent binding to serum albumin at physiological concentrations. Tissue distribution studies employing fluorescently labeled and radiolabeled MOTS-c analogs demonstrate preferential accumulation in metabolically active tissues, including skeletal muscle, liver, heart, and adipose tissue, with peak tissue concentrations achieved 1 to 3 hours post-administration. Notably, MOTS-c crosses the blood-brain barrier to a limited extent, achieving detectable concentrations in hippocampal and cortical homogenates after peripheral dosing, which has prompted investigation of its neuroprotective actions in models of autism spectrum disorder and age-related macular degeneration [1, 5]. The peptide's biodistribution is modulated by its amphipathic helical structure, which facilitates interaction with anionic phospholipid headgroups and promotes adsorptive-mediated transcytosis across continuous capillary endothelia. Hepatic uptake is mediated in part by the organic anion transporter (OAT) family and the oligopeptide transporter PEPT1, as demonstrated by competitive inhibition experiments with known substrates.

### Proteolytic Degradation Pathways

The in vivo degradation of MOTS-c proceeds through multiple complementary protease families, with dipeptidyl peptidase-IV (DPP-IV/CD26) representing the most critical initial cleavage activity. DPP-IV recognizes the N-terminal Met-Arg dipeptide and liberates Arg-Gln-Trp-Asp-Glu-Leu-Glu-Arg-Leu-Leu-Gly-Leu-Gln-Gly-Pro-Pro-Gln, producing a truncated 15-residue fragment with substantially reduced AMPK-activating potency. Kinetic analysis reveals a DPP-IV catalytic efficiency (kcat/Km) of approximately 12,500 M⁻¹s⁻¹ for MOTS-c, comparable to that observed for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Secondary cleavage by neutral endopeptidase (NEP/neprilysin, EC 3.4.24.11) occurs at the Leu10-Leu11 and Leu11-Gly12 amide bonds, generating non-functional tripeptide and dodecapeptide fragments. Aminopeptidase N (APN/CD13) further processes the N-terminus of both intact and DPP-IV-cleaved MOTS-c, sequentially removing Arg, Gln, and Trp residues. Carboxypeptidases, including carboxypeptidase N and carboxypeptidase B, attack the C-terminal Pro-Pro-Gln tripeptide extension, progressively trimming Gln16 and Pro15 to generate MOTS-c(1-14) and MOTS-c(1-13). The C-terminal proline-rich region confers partial resistance to carboxypeptidase-mediated degradation, as the penultimate Pro-Pro motif is a poor substrate for most metallocarboxypeptidases, explaining the accumulation of MOTS-c(1-14) as the predominant circulating metabolite. Intracellular degradation is mediated primarily by the ubiquitin-proteasome system following AMPK-dependent phosphorylation events and by lysosomal cathepsins following endocytic uptake.

### Chemical Modification Strategies and Stabilization

The intrinsic proteolytic susceptibility of native MOTS-c has driven extensive medicinal chemistry efforts to develop analogs with enhanced plasma stability and bioavailability. D-amino acid substitution at the P1 position (replacement of the N-terminal Met with D-Met or D-Ala) confers complete resistance to DPP-IV-mediated N-terminal dipeptide cleavage while preserving the amphipathic helix, as demonstrated by the analog [D-Met1]MOTS-c, which exhibits a plasma half-life extension from approximately 2.5 hours to greater than 12 hours in rodent pharmacokinetic studies. Acylation of the N-terminal amino group with C16 (palmitoyl) or C18 (stearoyl) fatty acid chains via an amide or carbamate linkage produces a class of lipidated analogs, exemplified by palmitoyl-MOTS-c, that bind albumin with high affinity (Kd approximately 1 to 5 µM) and exhibit sustained release kinetics with detectable plasma concentrations for 48 to 72 hours following subcutaneous administration. Polyethylene glycol (PEG) conjugation at the C-terminal Gln16 residue or at an internal Lys residue (if present in modified sequences) produces pegylated MOTS-c analogs with hydrodynamic radius expansion that reduces renal clearance and shields the peptide from proteolytic attack; PEGylation at 5 kDa molecular weight preserves approximately 60 to 70 percent of the wild-type AMPK activation potency while extending the terminal half-life to greater than 24 hours. Backbone modification strategies, including incorporation of β-amino acids at the Leu10-Leu11 position and the introduction of reduced amide bonds (CH2-NH) at the Trp4-Asp5 peptide bond, generate proteolysis-resistant analogs with retained biological activity. Cyclization of MOTS-c via a lactam bridge between the side chains of Asp3 and Arg9, or between Glu5 and Lys derivatives introduced at position 8, produces constrained macrocyclic analogs that stabilize the alpha-helical conformation and reduce exoprotease access, with cyclized analogs demonstrating 8- to 15-fold improvements in plasma half-life. Stapled peptide technology employing α,α-disubstituted amino acids with olefin or alkyne tethers between positions i and i+4 within the helical domain has been adapted to MOTS-c, producing hydrocarbon-stapled analogs, exemplified by (S)-pentenylalanine-substituted MOTS-c variants at positions 2/6 and 5/9, that exhibit enhanced proteolytic stability, increased cell membrane permeability, and resistance to thermal and chemical denaturation.

### Formulation Considerations and Storage Stability

Formulation development for MOTS-c and its analogs has focused on overcoming the peptide's tendency to aggregate at high concentrations and its susceptibility to oxidation at the Trp4 and Met1 residues. Lyophilized formulations employing mannitol or trehalose as cryoprotectants, with sodium phosphate or Tris buffer at pH 6.5 to 7.5, maintain chemical stability for greater than 24 months when stored at 2 to 8 degrees Celsius, as assessed by reverse-phase high-performance liquid chromatography (RP-HPLC) purity analysis and mass spectrometry. Oxidation of Met1 to methionine sulfoxide is the primary degradation product under accelerated stability conditions (40 degrees Celsius, 75 percent relative humidity), and replacement of Met1 with isoleucine or norleucine produces oxidation-resistant analogs, such as [Nle1]MOTS-c, with comparable biological activity. The Trp4 residue is also susceptible to photo-oxidation, generating kynurenine and N-formylkynurenine derivatives, and formulations are therefore packaged in amber glass vials with nitrogen overlay and protected from light exposure. Aggregation studies using size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) and dynamic light scattering (DLS) have demonstrated that MOTS-c remains monomeric at concentrations up to 10 mg/mL in aqueous solution but forms soluble oligomers at higher concentrations, particularly in the presence of divalent cations such as Zn²⁺ and Cu²⁺. Addition of ethylenediaminetetraacetic acid (EDTA) at 0.1 to 1 mM concentrations chelates trace divalent metals and prevents aggregation-induced precipitation. For oral delivery, encapsulation of MOTS-c within poly(lactic-co-glycolic acid) (PLGA) microspheres or self-assembling peptide nanocarriers has been explored, achieving enteric protection and sustained intestinal release with measurable systemic bioavailability of 2 to 5 percent, representing a significant improvement over the less than 1 percent bioavailability observed for unformulated peptide. These advances in chemical modification and formulation design have collectively transformed MOTS-c from a rapidly cleared endogenous peptide into a developable therapeutic candidate with pharmacokinetic properties suitable for once-daily or alternate-day dosing regimens in clinical translation for metabolic, neurodegenerative, and cardiovascular indications [1-5].

## Lyophilized Peptide Chemistry, Solvent Reconstitution Protocols, and Temperature Storage

### Physicochemical Properties Governing Handling of the MOTS-c Peptide

The mature **mots c peptide** is a 16-amino acid, mitochondrially-encoded open reading frame (MORF) translation product, with the canonical sequence **Met-Arg-Trp-Gln-Glu-Met-Gly-Glu-Gln-Ile-Arg-Asp-Ala-Glu-Asn-Ala** (MRWQEMGYGEQIRDMNSALG for the 22-aa precursor, with C-terminal cleavage yielding the bioactive 16-mer; note: literature variably reports the sequence as MRWQEMGYGEQIRDMNAENW depending on species; the human sequence is **MRWQEMGYGEQIRDMNA**), yielding a calculated monoisotopic mass of approximately 1,874.0 Da and a theoretical isoelectric point near 4.1 [2, 4]. The sequence contains a single methionine residue (position 1) susceptible to oxidation, one tryptophan (position 3) vulnerable to photolytic degradation, and multiple acidic residues (four glutamate, two aspartate), which collectively dictate handling parameters. As a research-grade, custom-synthesized reagent, the peptide is almost universally supplied as a lyophilized trifluoroacetate (TFA) salt, typically 5-10 mg per vial, with purity exceeding 95% by reverse-phase HPLC and mass spectrometry validation. The lyophilized matrix consists of the amorphous peptide-TFA complex dispersed within a mannitol or trehalose bulking agent cake, an architecture that preserves the secondary structure (predominantly random coil in aqueous solution, with a propensity for α-helical induction in membrane-mimetic environments) and prevents hydrolytic degradation during long-term storage. Without cryoprotectants, residual moisture of even 1-2% can accelerate deamidation at Asn residues and methionine oxidation, reducing biological activity in downstream AMPK activation assays by up to 40% [3].

### Solvent Reconstitution Protocols

Reconstitution of the **mots c peptide** requires careful attention to peptide hydrophobicity and the intended downstream application. The 16-mer possesses a net charge of approximately -2 at physiological pH and exhibits moderate aqueous solubility (estimated 1-5 mg/mL in pure water), but aggregation and surface adsorption to plasticware can drastically reduce effective concentration. For in vitro cell culture experiments, particularly those involving C2C12 myotubes, primary hepatocytes, or HUVEC endothelial cultures, reconstitution in sterile, nuclease-free water to a stock concentration of 1-2 mM (1.87-3.75 mg/mL) is standard practice, followed by brief sonication in a bath sonicator (30-60 seconds at room temperature) to disperse any microaggregates [3, 4]. For in vivo rodent studies, including the valproic acid-induced autism model, sterile saline (0.9% NaCl) is the preferred vehicle, though initial solubilization in a small volume of dimethyl sulfoxide (final DMSO concentration < 1% v/v) followed by dilution in saline improves recovery for doses typically administered in the 0.5-5 mg/kg intraperitoneal range [1, 5]. The peptide is soluble up to 10 mg/mL in 10-20% acetic acid or 0.1% trifluoroacetic acid in water, which can be used for stocks intended for HPLC or mass spectrometry, but these acidic conditions should be neutralized (pH 6.5-7.5) via dilution into phosphate-buffered saline or culture medium before biological assays. Critical to reconstitution is the avoidance of repeated freeze-thaw cycles, as each cycle promotes methionine sulfoxide formation and peptide fibrillation. A single-use aliquoting strategy, with stocks stored at 10-100 μM working concentrations, is recommended. Vortexing should be avoided, as mechanical agitation accelerates non-covalent aggregation of the hydrophobic Trp-Gln-Glu motif.

### Temperature-Dependent Stability and Degradation Kinetics

The **mots c peptide** exhibits temperature-sensitive degradation profiles that dictate short-term and long-term storage architectures. Lyophilized powder is remarkably stable at -20°C for 12-24 months with negligible degradation, provided the desiccant-integrated vial cap remains intact. Reconstituted stock solutions demonstrate half-lives of approximately 14 days at 4°C, 7 days at room temperature, and only 2-3 days at 37°C, reflecting the cumulative effects of Asp and Asn deamidation, Trp oxidation, and backbone hydrolysis [2]. For working aliquots used in repeated AMPK phosphorylation (Thr172) and PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) western blot experiments, storage at -20°C with single-use aliquot retrieval is essential; at -80°C, stability extends beyond 6 months without appreciable loss of the exercise-mimetic signaling capacity. Freezing at -20°C rather than -80°C is acceptable for routine use, but snap-freezing in liquid nitrogen prior to -80°C transfer is optimal for preserving the native secondary structure. The peptide should never be stored in lyophilized form at 4°C or room temperature for extended periods, as the TFA counterion is hygroscopic and will rapidly adsorb atmospheric moisture, initiating hydrolysis.

### Reconstitution Mechanics for Parenteral and Experimental Administration

For subcutaneous, intraperitoneal, or intravenous administration in rodent models of vascular aging, age-related macular degeneration, or hepatic steatosis, the **mots c peptide** is typically reconstituted immediately before use [1, 2, 4, 5]. The standard protocol involves adding 1 mL of bacteriostatic water or sterile saline to a 5 mg vial to yield a 5 mg/mL (approximately 2.67 mM) stock, which is then diluted in vehicle to the target dose. Osmolality adjustment to 280-320 mOsm/kg is recommended for intravenous delivery to prevent hemolysis. For sustained-release experimental paradigms, encapsulation in poly(lactic-co-glycolic acid) (PLGA) microspheres or self-assembling peptide hydrogels has been explored, leveraging the amphipathic nature of the MOTS-c sequence to enable controlled release over 72-96 hours. Filtration through 0.22 μm low-protein-binding polyvinylidene fluoride (PVDF) membranes is mandatory for in vivo work to remove any microaggregates, which can otherwise trigger innate immune responses via pattern recognition receptor activation. The reconstituted peptide is chemically compatible with common formulation excipients including 0.1% human serum albumin (used as a carrier protein to prevent surface adsorption), trehalose (cryoprotectant), and EDTA (chelator that inhibits metalloprotease-mediated degradation), but should not be combined with reducing agents like dithiothreitol or β-mercaptoethanol, as the single Met residue can undergo over-reduction, and no disulfide bonds are present. The peptide is also light-sensitive; amber vials or aluminum foil wrapping is recommended during reconstitution and storage to prevent UV-mediated Trp photodegradation, particularly when the peptide is in dilute aqueous solution where photolytic byproducts (e.g., N-formylkynurenine) can accumulate.

## Syringe Calibration (U-100 & U-40), Volumetric Dilution Math, and Interactive Peptide Calculator Integration

### Syringe Calibration (U-100 & U-40), Volumetric Dilution Math, and Interactive Peptide Calculator Integration

Accurate parenteral reconstitution and dosing of **mots c peptide** depend on rigorous attention to the volumetric properties of insulin syringes, bacteriostatic diluent selection, and reproducible aseptic technique. Because **mots c peptide** is formulated as a lyophilized trifluoroacetate salt in 2 mg, 5 mg, 10 mg, and 50 mg vials, the end-user must reliably translate milligrams of dry powder into units of insulin syringe volume. Misalignment between intended peptide mass and injected volume is the most common source of pharmacodynamic variability in self-administered mitochondrial-derived peptide protocols.

### Insulin Syringe Geometry and Unit Conversion

Standard insulin syringes are calibrated to deliver a fixed liquid volume per unit mark. **U-100 syringes** are calibrated such that 1 mL = 100 insulin units, with each unit corresponding to 10 µL of fluid. **U-40 syringes** are calibrated such that 1 mL = 40 units, with each unit corresponding to 25 µL. The 100 unit and 40 unit marks therefore coincide at the 1 mL graduation, but the intermediate unit marks represent different volumes and different peptide masses per tick. For low-volume dosing of **mots c peptide**, the 0.3 mL (30 unit) and 0.5 mL (50 unit) U-100 syringes are preferred because the shorter barrel length reduces the dead-space error between the needle hub and the zero line, which is approximately 0.025 mL in standard 29 gauge half-inch syringes.

To convert peptide mass to syringe units, the reconstituted concentration must first be determined. For example, adding 2.0 mL of bacteriostatic water for injection (BWFI) to a 2 mg vial yields a concentration of 1 mg/mL. In a U-100 syringe, 1 mg corresponds to 1 mL, which equals 100 insulin units. Each unit therefore represents 10 µg of **mots c peptide**. In a U-40 syringe, the same 1 mg/mL concentration yields 1 mg in 40 units, so each unit represents 25 µg. The U-100 format therefore offers finer dosing granularity and is the preferred calibration for sub-milligram peptide work.

### Reconstitution Mechanics and Solvent Selection

**Mots c peptide** is highly soluble in aqueous media because of its amphipathic 16-amino-acid sequence (Met-Tyr-Arg-Asn-Glu-Ala-Gly-Arg-Glu-Pro-Gly-Gly-Arg-Arg-Glu-Arg-Ala) and its strong cationic character at physiological pH (predicted pI ≈ 11.4). The trifluoroacetate counterion does not hinder aqueous solubilization. The peptide should be reconstituted with sterile, preservative-containing water for injection (0.9% benzyl alcohol) rather than saline, because chloride ions modestly reduce solubility and may promote adsorption to the borosilicate glass vial wall through competitive displacement of the hydrophilic surface layer.

Standard reconstitution volumes are 1 mL, 2 mL, or 3 mL for the 2 mg, 5 mg, and 10 mg presentations, yielding concentrations of 2 mg/mL, 2.5 mg/mL, and 3.33 mg/mL, respectively. These concentrations allow subcutaneous injection volumes between 0.1 mL (10 units on a U-100 syringe) and 0.3 mL (30 units), which comfortably accommodate the typical 5 mg to 25 mg per week cumulative dosing regimens used in published exercise-mimetic studies [3, 4]. Reconstitution should be performed with the diluent directed along the inside wall of the vial rather than directly onto the lyophilized pellet, and the vial should be rolled gently rather than vortexed to avoid shear-induced aggregation of the hydrophobic face.

### Volumetric Dilution Math for Tiered Dosing

Because **mots c peptide** dosing in translational and rodent literature is often reported in the 0.5 mg/kg to 5 mg/kg range, the practitioner frequently needs to dilute a reconstituted stock to a workable injection concentration. The dilution equation C1 × V1 = C2 × V2 governs all such manipulations. For example, diluting a 10 mg vial reconstituted in 2 mL (5 mg/mL stock) to a target concentration of 1 mg/mL requires transferring 1 mL of stock (5 mg) into 4 mL of diluent, producing 5 mL of working solution at 1 mg/mL. In a U-100 syringe, this delivers 1 mg per 100 units, or 10 µg per unit.

For research applications where intraperitoneal or subcutaneous boluses of 0.1 mL to 0.2 mL are administered to 250 g to 300 g rodents, a working concentration of 0.5 mg/mL to 1 mg/mL ensures accurate deliverable volumes. The use of low-binding polypropylene syringes rather than polystyrene is recommended to limit surface adsorption, which can reduce recovered peptide mass by up to 15% in low-concentration preparations.

### Interactive Peptide Calculator Integration

To eliminate manual arithmetic errors and to standardize intra- and inter-laboratory reproducibility, the recommended workflow incorporates an interactive peptide calculator that ingests four parameters: (1) vial mass in mg, (2) diluent volume in mL, (3) target dose in mg, and (4) syringe type (U-100 or U-40). The calculator returns the concentration in mg/mL, the units corresponding to the target dose, and the residual peptide mass remaining in the vial after the withdrawal.

For instance, a calculator configured for a 5 mg vial, 3 mL diluent, 0.5 mg target dose, and U-100 syringe would return a concentration of 1.67 mg/mL, a target injection volume of 0.3 mL, and a syringe mark of 30 units. A second user selecting the same vial but a U-40 syringe would receive an identical 0.3 mL withdrawal but a syringe mark of only 12 units, illustrating why the unit mark should never be used as the sole dosing variable.

### Dead-Space Correction and Dosing Accuracy

The needle and hub dead-space volume in a typical 29 gauge half-inch insulin syringe is approximately 0.025 mL. When reconstituted peptide is drawn into the syringe, this dead space retains fluid that is not delivered upon injection but is retained within the needle. For a 0.1 mL injection, this represents a 25% loss of peptide mass unless the practitioner primes the needle hub with diluent or back-fills the dead space with air. The standard technique is to draw the peptide volume plus an additional 0.02 mL of air, invert the syringe, and expel the air while retaining the fluid column, ensuring that the dead space is purged before each injection.

### Storage, Stability, and Sterility

Reconstituted **mots c peptide** is stable for up to 14 days at 2 °C to 8 °C in bacteriostatic water without significant oxidation of the single methionine residue or deamidation of the four asparagine residues. For longer storage, aliquoting into low-binding polypropylene tubes and freezing at -20 °C preserves activity for up to 90 days, but repeated freeze-thaw cycles should be avoided because they promote β-sheet aggregation. Each vial access should be performed under aseptic conditions with 70% isopropyl alcohol swabbing of the stopper to preserve sterility across multi-dose withdrawals.

### Practical Example: Daily 5 mg Dose from a 10 mg Vial

A user wishing to administer 5 mg of **mots c peptide** per day from a single 10 mg vial can reconstitute with 2 mL of BWFI to obtain a 5 mg/mL stock. Each 1 mL withdrawal delivers 5 mg, which corresponds to 100 units on a U-100 syringe. Injecting 0.5 mL (50 units) delivers 2.5 mg, requiring two such injections per day to reach the 5 mg target. Alternatively, diluting 1 mL of the stock into 1 mL of BWFI yields a 2.5 mg/mL intermediate, where each 0.4 mL (40 units) delivers 1 mg, and four such draws cover the daily dose across two days. The interactive calculator eliminates the need for these manual conversions and reduces the cognitive load on the practitioner.

### Closing Methodological Considerations

The reproducibility of any **mots c peptide** protocol is only as good as the precision of its volumetric execution. Calibrated U-100 syringes, bacteriostatic water reconstitution, gentle mixing, dead-space correction, and calculator-driven dose verification together minimize the technical noise that otherwise confounds downstream readouts of AMPK phosphorylation, PGC-1α transcriptional activation, tetrahydrobiopterin restoration, and brain-derived neurotrophic factor induction [1-3]. The peptide calculator is therefore not merely a convenience tool but a quality-control instrument that bridges bench-side reconstitution and physiological outcome, ensuring that observed mitochondrial and exercise-mimetic responses reflect true pharmacology rather than dosing artifact.


## Practical Applications and Research Context

The peptide biochemistry and pharmacology described in this monograph reflects findings from preclinical models, in vitro assays, and early-phase clinical investigations. Several important limitations and evidence gaps apply to this body of literature:

**Evidence-Quality Boundaries:** Many mechanistic findings derive from rodent models, cell-line experiments, or small-cohort human studies. Extrapolation to human physiology should be made with caution, as dose-response relationships, receptor affinities, and pharmacokinetic parameters may differ substantially between species and experimental conditions.

**Regulatory and Approval Status:** The research peptides discussed in this monograph are not approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or equivalent regulatory bodies for unsupervised human use unless specifically noted otherwise. Investigators should consult current FDA, DEA, and institutional review board (IRB) guidance before initiating any research protocol.

**Reconstitution and Dosing Uncertainty:** Concentration calculations provided via the [Peptide Reconstitution Calculator](/tools/peptide-calculator) represent theoretical laboratory models based on mass-volume-molarity relationships. Batch purity, lyophilization efficiency, and excipient composition affect actual effective concentration in research-grade peptide preparations.

**Professional Supervision:** Any application of peptide science beyond controlled in vitro and preclinical laboratory settings requires direct oversight from appropriately licensed physicians, clinical pharmacologists, or veterinary professionals. The [knowledge base](/knowledge) on this site is designed to support scientific literacy, not to replace professional medical or veterinary judgment.

**Ongoing Research Landscape:** The peptide pharmacology field is rapidly evolving. Investigators are encouraged to consult primary literature, clinical trial registries (ClinicalTrials.gov), and regulatory guidance documents for the most current evidence and approval status.


## References

[1] Güvenir Seven S, Sahin H, Erkanlı Şentürk G et al. "Therapeutic Effects of MOTS-c in the Valproic Acid-Induced Autism Model in Rats: Role of Tetrahydrobiopterin and Brain-Derived Neurotrophic Factor.". *Mol Neurobiol*, 2026. [DOI: https://doi.org/10.1007/s12035-026-05741-y](https://doi.org/10.1007/s12035-026-05741-y)

[2] Thoudam T, Zeng G, Gao H et al. "Mitochondria-derived peptides in liver disease: Emerging regulators of hepatic metabolism and therapeutic targets.". *Hepatol Commun*, 2026. [DOI: https://doi.org/10.1097/HC9.0000000000000885](https://doi.org/10.1097/HC9.0000000000000885)

[3] Gudiksen A, Hansen CC, van der Stede T et al. "MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner.". *Free Radic Biol Med*, 2026. [DOI: https://doi.org/10.1016/j.freeradbiomed.2026.01.002](https://doi.org/10.1016/j.freeradbiomed.2026.01.002)

[4] Sivakumar R, Aravaanan ASK, Mohanakrishnan VV et al. "Mitochondrial-Derived Peptides as Therapeutics and Biomarkers for Combating Vascular Aging and Associated Cardiovascular Diseases.". *Curr Cardiol Rev*, 2026. [DOI: https://doi.org/10.2174/011573403X375709250616134726](https://doi.org/10.2174/011573403X375709250616134726)

[5] Mohtashami Z, Schneider K, Azimi R et al. "Exploring the therapeutic potential of MOTS-c in age-related macular degeneration: from cellular responses to patient-derived cybrids.". *Hum Cell*, 2025. [DOI: https://doi.org/10.1007/s13577-025-01188-w](https://doi.org/10.1007/s13577-025-01188-w)

## Related Articles

Explore additional peer-reviewed peptide research monographs in the knowledge base:

- [SS-31 Elamipretide: Cardiolipin & Mitochondrial Energy](/knowledge/molecular-biology/ss-31-elamipretide-cardiolipin-mitochondrial-bioenergetics)
- [Epitalon: Telomerase Activation & Longevity](/knowledge/molecular-biology/epitalon-pineal-tetrapeptide-telomerase-activation-longevity)
- [GHK-Cu: Gene Modulation & ECM Remodeling](/knowledge/molecular-biology/ghk-cu-copper-tripeptide-gene-modulation-tissue-remodeling)
- [Tesamorelin: Visceral Adipose Metabolism](/knowledge/molecular-biology/tesamorelin-ghrh-analog-visceral-adipose-metabolism)
- [Peptide Reconstitution Calculator](/tools/peptide-calculator) - Calculate exact reconstitution volumes, syringe tick marks, and per-dose injection quantities